文献速递类风湿关节炎

TNF抑制剂与其他生物制剂对类风湿关节炎心血管风险相关生物标志物的对比效应

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.
PubMed 文献 · RMD Open · 2019-07-21

基于ROC试验的二次分析,纳入203例对TNF抑制剂控制不佳的RA患者,比较换用第二种TNF抑制剂与其他生物制剂(托珠单抗、利妥昔单抗或阿巴西普)24周内对心血管风险相关生物标志物的影响。结果显示两组生物标志物均未恶化,但其他生物制剂组LAR改善更显著,托珠单抗组Lp(a)改善优于TNF抑制剂组。

要点

  • 两组生物标志物从基线到24周均未恶化。
  • 其他生物制剂组LAR改善优于TNF抑制剂组(p=0.033)。
  • 托珠单抗组Lp(a)改善优于TNF抑制剂组(p<0.001)。

核心结论

  • 在TNF抑制剂控制不足的RA患者中,TNF抑制剂与非TNF抑制剂对CVD风险相关生物标志物均呈中性效应。

研究设计与样本

  • ROC试验的二次分析,纳入203例RA患者,其中96例接受第二种TNF抑制剂、107例接受其他生物制剂(托珠单抗、利妥昔单抗或阿巴西普),评估基线及24周血清ApoA1、ApoB100、Lp(a)及LAR变化。

主要发现

  • 两组生物标志物从基线到第24周均未恶化。
  • 其他生物制剂组LAR改善大于TNF抑制剂组(中位数(IQR)-0.12 ng/µg(-0.58至0.31)vs 0.04(-0.19至0.43),p=0.033)。
  • 托珠单抗组Lp(a)改善大于TNF抑制剂组(-0.05 g/L(-0.11至-0.01)vs -0.01 g/L(-0.02至0.01),p<0.001)。
  • 生物标志物改善主要见于各治疗组的EULAR应答者。

关键数值与推荐

  • LAR变化:其他生物制剂组中位数(IQR)-0.12 ng/µg(-0.58至0.31)vs TNF抑制剂组0.04(-0.19至0.43),p=0.033。
  • Lp(a)变化:托珠单抗组-0.05 g/L(-0.11至-0.01)vs TNF抑制剂组-0.01 g/L(-0.02至0.01),p<0.001。

临床怎么用

  • 对于TNF抑制剂控制不足的RA患者,换用托珠单抗可能有助于改善Lp(a)和LAR,但需结合治疗应答综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA). METHODS: We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24. We compared the changes in biomarker levels in each group and according to the EULAR response. RESULTS: Of the 300 patients enrolled in the ROC trial, 203 were included in the study, including 96 in the second-line TNFi group and 107 in the other biological group. The measured biomarkers did not deteriorate between baseline and week 24 regardless of the group. A greater improvement in the LAR was noted in the other biological group (median (IQR) -0.12 ng/µg (-0.58 to 0.31) vs 0.04 (-0.19 to 0.43), p=0.033), and a greater improvement in the Lp(a) level was observed following treatment with TCZ than with a TNFi (-0.05 g/L (-0.11 to -0.01) vs -0.01 g/L (-0.02 to 0.01), p<0.001). When considering the patients' responses to treatment, improved biomarkers were mainly observed in the EULAR responders in each treatment group. CONCLUSIONS: TNFis and non-TNFis were neutral on improved CVD risk-associated biomarkers in patients with RA insufficiently controlled by TNFis. TCZ could be associated with a better improvement concerning Lp(a) and LAR than TNFis. This improvement could be related to a good therapeutic response, thereby supporting the need of good control of RA. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Identifier NCT01000441, registered on 22 October 2009.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Virone A, Bastard JP, Fellahi S, et al. Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. RMD Open. 2019. PMID: 31413865. doi:10.1136/rmdopen-2019-000897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。